ATE392901T1 - Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen - Google Patents

Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen

Info

Publication number: ATE392901T1
Authority: AT; Austria
Prior art keywords: mucuna pruriens; preparation; pharmaceutical composition; neurological diseases; substances
Prior art date: 2002-10-30

Application number

AT03809721T

Other languages

English (en)

Inventor

Der Giessen Robert H M Van

Waren Olanow

Andrew Lees

Hildebert Wagner

Original Assignee

Phytrix Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-30

Filing date

2003-10-02

Publication date

2008-05-15

2003-10-02 Application filed by Phytrix Ag filed Critical Phytrix Ag

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE392901T1 publication Critical patent/ATE392901T1/de

Links

244000111261 Mucuna pruriens Species 0.000 title abstract 8
235000006161 Mucuna pruriens Nutrition 0.000 title abstract 8
239000000284 extract Substances 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000000926 neurological effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 5
239000000126 substance Substances 0.000 abstract 4
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 3
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 3
208000012902 Nervous system disease Diseases 0.000 abstract 2
208000025966 Neurological disease Diseases 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000004112 neuroprotection Effects 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Psychology (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines Containing Plant Substances (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Electrotherapy Devices (AREA)
Apparatus For Radiation Diagnosis (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03809721T 2002-10-30 2003-10-02 Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen ATE392901T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02024475		2002-10-30

Publications (1)

Publication Number	Publication Date
ATE392901T1 true ATE392901T1 (de)	2008-05-15

Family

ID=32187158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03809721T ATE392901T1 (de)	2002-10-30	2003-10-02	Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen

Country Status (8)

Country	Link
US (1)	US7470441B2 (de)
EP (1)	EP1567177B1 (de)
JP (1)	JP2006507288A (de)
AT (1)	ATE392901T1 (de)
AU (1)	AU2003276041A1 (de)
CA (1)	CA2504201A1 (de)
DE (1)	DE60320579D1 (de)
WO (1)	WO2004039385A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8142800B1 (en) *	2001-12-18	2012-03-27	Tamea Rae Sisco	Oral high potency clinical anti-craving treatment and method of use
CA2556169C (en) *	2004-01-29	2011-11-22	Andrew Lees	Use of amino-oxy functional groups in the preparation of vaccines
US20050202111A1 (en) *	2004-03-04	2005-09-15	Manyam Bala V.	Anti-Parkinson's disease pharmaceutical and method of use
WO2010121159A1 (en) *	2009-04-17	2010-10-21	Somalabs, Inc.	Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system
WO2011017101A2 (en)	2009-07-27	2011-02-10	Fina Biosolutions, Llc	Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
CA2836153C (en)	2009-12-17	2016-06-21	Fina Biosolutions, Llc	Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP2560738B8 (de)	2010-04-23	2019-09-25	Serum Institute of India Private Limited	Einfaches verfahren zur simultanen beseitigung mehrerer unreinheiten aus kulturüberständen auf extrem geringe konzentrationen
KR101063935B1 (ko) *	2010-07-16	2011-09-14	한국전기연구원	자기정렬법을 이용한 탄화규소 전계효과 트랜지스터 소자의 제조방법
WO2018222781A2 (en) *	2017-05-30	2018-12-06	Emerson Paul G	Compositions and methods to regulate hormonal cascades in stress disorders
WO2019060661A1 (en)	2017-09-22	2019-03-28	Iowa State University Research Foundation, Inc.	PROBIOTIC COMPOSITIONS FOR THE PRODUCTION OF DOPAMINE
WO2020076485A2 (en) *	2018-09-21	2020-04-16	Iowa State University Research Foundation, Inc.	Genetic elements in enterococcus spp. to produce dopamine
CN109096131B (zh) *	2018-09-28	2021-01-15	那坡康正天然植物提取有限责任公司	一种利用猫豆制备左旋多巴的工艺
CN109081787B (zh) *	2018-09-28	2021-01-15	那坡康正天然植物提取有限责任公司	一种从黎豆中提取左旋多巴的工艺
WO2022192275A1 (en) *	2021-03-08	2022-09-15	University Of Connecticut	Assisted loading of hydrophobic molecules into liposomes
US12350300B2 (en)	2021-10-08	2025-07-08	Iowa State University Research Foundation, Inc.	Use of dopamine producing products to increase vaccine efficacy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941835A (en) *	1970-03-19	1976-03-02	Bio-Derivatives Corporation	Recovery of L-Dopa from R-dopa containing materials
US3666802A (en) *	1970-05-04	1972-05-30	Millmaster Onyx Corp	Recovery of 3-(3,4-dihydroxyphenyl)-l-alanine from beans with water
US6106839A (en) *	1999-05-29	2000-08-22	Pruthi; Som C.	Ayurvedic composition for the treatment of disorders of the nervous system including Parkinson's disease
WO2002069921A1 (en) *	2001-03-07	2002-09-12	Unilever Plc	Hair colouring compositions

2003
- 2003-10-02 WO PCT/EP2003/010975 patent/WO2004039385A2/en not_active Ceased
- 2003-10-02 DE DE60320579T patent/DE60320579D1/de not_active Expired - Lifetime
- 2003-10-02 AT AT03809721T patent/ATE392901T1/de not_active IP Right Cessation
- 2003-10-02 JP JP2004547503A patent/JP2006507288A/ja not_active Withdrawn
- 2003-10-02 CA CA002504201A patent/CA2504201A1/en not_active Abandoned
- 2003-10-02 EP EP03809721A patent/EP1567177B1/de not_active Expired - Lifetime
- 2003-10-02 AU AU2003276041A patent/AU2003276041A1/en not_active Abandoned
- 2003-10-02 US US10/533,135 patent/US7470441B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2006507288A (ja)	2006-03-02
WO2004039385A2 (en)	2004-05-13
EP1567177A2 (de)	2005-08-31
WO2004039385A3 (en)	2004-07-01
AU2003276041A1 (en)	2004-05-25
DE60320579D1 (de)	2008-06-05
EP1567177B1 (de)	2008-04-23
US7470441B2 (en)	2008-12-30
US20060165822A1 (en)	2006-07-27
CA2504201A1 (en)	2004-05-13
AU2003276041A8 (en)	2004-05-25

Legal Events

Date	Code	Title	Description
2008-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE392901T1 (de)	2008-05-15	Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen
WO2001009118A3 (en)	2001-11-22	Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
LUC00011I1 (de)	2017-04-06
TW200501983A (en)	2005-01-16	Uses of anti-insulin-like growth factor I receptor antibodies
AU2003301190A1 (en)	2004-07-14	Administration of capsaicinoids
ZA200503656B (en)	2009-02-25	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
DE60218193D1 (de)	2007-03-29	Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MXPA05011432A (es)	2006-03-21	Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
TW200505909A (en)	2005-02-16	Arylvinylazacycloalkane compounds and methods of preparation and use thereof
AU2001266289A1 (en)	2002-01-02	2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
BRPI0410651A (pt)	2006-07-04	composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
TW200728300A (en)	2007-08-01	Therapeutic agents
BR0317772A (pt)	2005-11-22	Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
ATE482217T1 (de)	2010-10-15	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
WO2003066806A3 (en)	2003-12-24	Therapeutic use of aziridino compounds
NZ608560A (en)	2015-05-29	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions
DE60308127D1 (de)	2006-10-19	Pharmazeutische Zusammentsetzung zur medizinischen Behandlung von gutartiger prostathyperplasie, dessen Vorbereitungsmethode und dessen therapeutische Verwendung